Trial Outcomes & Findings for Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (NCT NCT02651987)

NCT ID: NCT02651987

Last Updated: 2022-10-03

Results Overview

PFS was defined as the time from first injection of lanreotide Autogel® 120 mg every 14 days to progression or death. Disease progression was assessed by tumour response evaluation according to RECIST v1.0, every 12 weeks, measured by independent central review using the same imaging technique (computed tomography \[CT\] scan or magnetic resonance imaging \[MRI\]) for each subject throughout the study. The median PFS time was estimated using the Kaplan Meier method for each cohort.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 99 participants
• Primary outcome timeframe: From Day 1 up to Week 60 for the panNET cohort and Week 103 for the midgut NET cohort
• Results posted on: 2022-10-03

Participant Flow

Subjects with well differentiated, metastatic or locally advanced, unresectable, pancreatic or midgut neuroendocrine tumours (NETs) and who had radiologically documented disease progression as per Response Evaluation Criteria in Solid Tumours (RECIST) v1.0 whilst receiving treatment with lanreotide Autogel® 120mg, every 28 days for at least 24 weeks were enrolled into this study in 25 centres across 10 countries.

Subjects who had centrally reviewed, radiologically documented disease progression within 24 months prior to enrolment and whilst receiving treatment with lanreotide Autogel® 120 mg, administered every 28 days for at least 24 weeks, were recruited into one of two cohorts based on the primary location of NET (i.e. pancreatic NET [panNET] or midgut NET cohort).

Participant milestones

Measure	Pancreatic NET (panNET) Cohort Subjects were treated with lanreotide Autogel® 120 mg, administered as deep subcutaneous (SC) injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (progressive disease \[PD\] or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.
Overall Study STARTED	48	51
Overall Study COMPLETED	43	46
Overall Study NOT COMPLETED	5	5

Reasons for withdrawal

Measure	Pancreatic NET (panNET) Cohort Subjects were treated with lanreotide Autogel® 120 mg, administered as deep subcutaneous (SC) injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (progressive disease \[PD\] or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.
Overall Study Adverse Event	2	2
Overall Study Consent Withdrawn	2	0
Overall Study Local PD	0	2
Overall Study Investigator Decision	1	1

Baseline Characteristics

French local regulation does not allow the collection of race and therefore French subjects are not included in this baseline measure.

Baseline characteristics by cohort

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Total n=99 Participants Total of all reporting groups
Age, Continuous	63.3 years STANDARD_DEVIATION 10.6 • n=48 Participants	67.1 years STANDARD_DEVIATION 8.2 • n=51 Participants	65.2 years STANDARD_DEVIATION 9.6 • n=99 Participants
Sex: Female, Male Female	28 Participants n=48 Participants	22 Participants n=51 Participants	50 Participants n=99 Participants
Sex: Female, Male Male	20 Participants n=48 Participants	29 Participants n=51 Participants	49 Participants n=99 Participants
Race/Ethnicity, Customized Race · Asian	0 Participants n=36 Participants • French local regulation does not allow the collection of race and therefore French subjects are not included in this baseline measure.	1 Participants n=38 Participants • French local regulation does not allow the collection of race and therefore French subjects are not included in this baseline measure.	1 Participants n=74 Participants • French local regulation does not allow the collection of race and therefore French subjects are not included in this baseline measure.
Race/Ethnicity, Customized Race · White	35 Participants n=36 Participants • French local regulation does not allow the collection of race and therefore French subjects are not included in this baseline measure.	37 Participants n=38 Participants • French local regulation does not allow the collection of race and therefore French subjects are not included in this baseline measure.	72 Participants n=74 Participants • French local regulation does not allow the collection of race and therefore French subjects are not included in this baseline measure.
Race/Ethnicity, Customized Race · Other	1 Participants n=36 Participants • French local regulation does not allow the collection of race and therefore French subjects are not included in this baseline measure.	0 Participants n=38 Participants • French local regulation does not allow the collection of race and therefore French subjects are not included in this baseline measure.	1 Participants n=74 Participants • French local regulation does not allow the collection of race and therefore French subjects are not included in this baseline measure.
Region of Enrollment Netherlands	1 participants n=48 Participants	3 participants n=51 Participants	4 participants n=99 Participants
Region of Enrollment Belgium	3 participants n=48 Participants	2 participants n=51 Participants	5 participants n=99 Participants
Region of Enrollment Ireland	2 participants n=48 Participants	0 participants n=51 Participants	2 participants n=99 Participants
Region of Enrollment Denmark	1 participants n=48 Participants	2 participants n=51 Participants	3 participants n=99 Participants
Region of Enrollment Poland	12 participants n=48 Participants	10 participants n=51 Participants	22 participants n=99 Participants
Region of Enrollment Italy	2 participants n=48 Participants	6 participants n=51 Participants	8 participants n=99 Participants
Region of Enrollment United Kingdom	6 participants n=48 Participants	9 participants n=51 Participants	15 participants n=99 Participants
Region of Enrollment France	12 participants n=48 Participants	13 participants n=51 Participants	25 participants n=99 Participants
Region of Enrollment Germany	8 participants n=48 Participants	3 participants n=51 Participants	11 participants n=99 Participants
Region of Enrollment Spain	1 participants n=48 Participants	3 participants n=51 Participants	4 participants n=99 Participants
Quality of Life (QoL) Questionnaire Core 30 (QLQ-C30) Score	68.12 score on a scale STANDARD_DEVIATION 19.74 • n=46 Participants • Only subjects who had a QLQ-C30 measure at baseline are included.	67.83 score on a scale STANDARD_DEVIATION 20.76 • n=50 Participants • Only subjects who had a QLQ-C30 measure at baseline are included.	67.97 score on a scale STANDARD_DEVIATION 20.17 • n=96 Participants • Only subjects who had a QLQ-C30 measure at baseline are included.
EuroQoL 5 Dimensions, 5 Levels (EQ-5D-5L) v1.0 Questionnaire Descriptive System Score	0.82 score on a scale STANDARD_DEVIATION 0.17 • n=45 Participants • Only subjects with a EQ-5D-5L index value at baseline are included.	0.83 score on a scale STANDARD_DEVIATION 0.14 • n=45 Participants • Only subjects with a EQ-5D-5L index value at baseline are included.	0.83 score on a scale STANDARD_DEVIATION 0.15 • n=90 Participants • Only subjects with a EQ-5D-5L index value at baseline are included.
EQ-5D-5L Visual Analogue Scale (VAS) Score	75.02 score on a scale STANDARD_DEVIATION 17.93 • n=47 Participants • Only subjects with a EQ-5D-5L VAS score at baseline are included.	70.45 score on a scale STANDARD_DEVIATION 14.93 • n=44 Participants • Only subjects with a EQ-5D-5L VAS score at baseline are included.	72.81 score on a scale STANDARD_DEVIATION 16.62 • n=91 Participants • Only subjects with a EQ-5D-5L VAS score at baseline are included.
QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21) Score Endocrine Symptoms	16.54 score on a scale STANDARD_DEVIATION 22.30 • n=45 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	19.73 score on a scale STANDARD_DEVIATION 22.82 • n=49 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	18.20 score on a scale STANDARD_DEVIATION 22.51 • n=94 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.
QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21) Score Gastrointestinal Symptoms	21.70 score on a scale STANDARD_DEVIATION 20.01 • n=45 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	22.04 score on a scale STANDARD_DEVIATION 17.17 • n=49 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	21.88 score on a scale STANDARD_DEVIATION 18.48 • n=94 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.
QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21) Score Treatment Related Symptoms	11.63 score on a scale STANDARD_DEVIATION 13.11 • n=32 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	11.46 score on a scale STANDARD_DEVIATION 13.75 • n=32 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	11.55 score on a scale STANDARD_DEVIATION 13.33 • n=64 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.
QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21) Score Social Function	32.84 score on a scale STANDARD_DEVIATION 24.18 • n=45 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	35.03 score on a scale STANDARD_DEVIATION 24.33 • n=49 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	33.98 score on a scale STANDARD_DEVIATION 24.15 • n=94 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.
QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21) Score Disease Related Worries	44.44 score on a scale STANDARD_DEVIATION 29.96 • n=45 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	44.22 score on a scale STANDARD_DEVIATION 25.83 • n=49 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	44.33 score on a scale STANDARD_DEVIATION 27.74 • n=94 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.
QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21) Score Muscle/Bone Pain	26.52 score on a scale STANDARD_DEVIATION 30.99 • n=44 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	25.69 score on a scale STANDARD_DEVIATION 30.16 • n=48 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	26.09 score on a scale STANDARD_DEVIATION 30.39 • n=92 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.
QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21) Score Sexual Function	22.58 score on a scale STANDARD_DEVIATION 30.29 • n=31 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	17.86 score on a scale STANDARD_DEVIATION 27.94 • n=28 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	20.34 score on a scale STANDARD_DEVIATION 29.04 • n=59 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.
QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21) Score Information/Communication Function	3.70 score on a scale STANDARD_DEVIATION 12.76 • n=45 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	4.17 score on a scale STANDARD_DEVIATION 11.14 • n=48 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	3.94 score on a scale STANDARD_DEVIATION 11.89 • n=93 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.
QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21) Score Body Image	10.61 score on a scale STANDARD_DEVIATION 23.60 • n=44 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	15.56 score on a scale STANDARD_DEVIATION 28.95 • n=45 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.	13.11 score on a scale STANDARD_DEVIATION 26.41 • n=89 Participants • Only subjects who had a QLQ GI.NET21 measure at baseline are included.
Categories of Proliferation index Ki67 ≥10%	7 participants n=48 Participants	4 participants n=51 Participants	11 participants n=99 Participants
Categories of Proliferation index Ki67 <10%	41 participants n=48 Participants	46 participants n=51 Participants	87 participants n=99 Participants
Categories of Proliferation index Ki67 Missing	0 participants n=48 Participants	1 participants n=51 Participants	1 participants n=99 Participants
Tumour grading (according to WHO 2010 classification) Grade 1	12 participants n=48 Participants	29 participants n=51 Participants	41 participants n=99 Participants
Tumour grading (according to WHO 2010 classification) Grade 2	36 participants n=48 Participants	22 participants n=51 Participants	58 participants n=99 Participants
Hepatic tumour load >25%	7 participants n=48 Participants	9 participants n=51 Participants	16 participants n=99 Participants
Hepatic tumour load ≤25%	41 participants n=48 Participants	42 participants n=51 Participants	83 participants n=99 Participants

PRIMARY outcome

Timeframe: From Day 1 up to Week 60 for the panNET cohort and Week 103 for the midgut NET cohort

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

PFS was defined as the time from first injection of lanreotide Autogel® 120 mg every 14 days to progression or death. Disease progression was assessed by tumour response evaluation according to RECIST v1.0, every 12 weeks, measured by independent central review using the same imaging technique (computed tomography [CT] scan or magnetic resonance imaging [MRI]) for each subject throughout the study. The median PFS time was estimated using the Kaplan Meier method for each cohort.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Median Progression Free Survival (PFS)	5.6 months Interval 5.5 to 8.3	8.3 months Interval 5.6 to 11.1	—

SECONDARY outcome

Timeframe: From Day 1 up to Week 60 for the panNET cohort and Week 103 for the midgut NET cohort

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

Time to Progression was defined as time from first injection of lanreotide Autogel® 120 mg every 14 days to progression. Disease progression was assessed by tumour response evaluation according to RECIST v1.0, every 12 weeks, measured by independent central review using the same imaging technique (CT scan or MRI) for each subject throughout the study. Median time to progression was estimated using the Kaplan Meier method for each cohort.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Median Time to Progression	5.6 months Interval 5.5 to 8.3	8.7 months Interval 8.3 to 13.9	—

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, 48, 60 (for both cohorts) and Weeks 72, 84 and 96 (for midgut NET cohort)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

The percentage of subjects alive and progression-free was assessed throughout the study up to Week 60 for the panNET cohort and Week 96 for the midgut cohort. Disease progression was assessed by tumour response evaluation according to RECIST v1.0, every 12 weeks measured by independent central review using the same imaging technique (CT scan or MRI) for each subject throughout the study. The percentage of subjects alive and progression free was estimated using the Kaplan Meier method for each cohort.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Percentage of Subjects Alive and Progression Free Week 12	93.3 percentage of subjects Interval 80.7 to 97.8	91.8 percentage of subjects Interval 79.7 to 96.9	—
Percentage of Subjects Alive and Progression Free Week 24	64.4 percentage of subjects Interval 48.7 to 76.5	65.3 percentage of subjects Interval 50.3 to 76.8	—
Percentage of Subjects Alive and Progression Free Week 36	37.8 percentage of subjects Interval 23.9 to 51.6	59.2 percentage of subjects Interval 44.2 to 71.4	—
Percentage of Subjects Alive and Progression Free Week 48	28.5 percentage of subjects Interval 16.2 to 42.1	38.3 percentage of subjects Interval 24.8 to 51.6	—
Percentage of Subjects Alive and Progression Free Week 60	20.7 percentage of subjects Interval 9.0 to 35.7	36.1 percentage of subjects Interval 22.9 to 49.5	—
Percentage of Subjects Alive and Progression Free Week 72	—	29.8 percentage of subjects Interval 17.6 to 42.9	—
Percentage of Subjects Alive and Progression Free Week 84	—	27.5 percentage of subjects Interval 15.7 to 40.5	—
Percentage of Subjects Alive and Progression Free Week 96	—	25.2 percentage of subjects Interval 13.9 to 38.1	—

SECONDARY outcome

Timeframe: From Day 1 up to Week 60 for the panNET cohort and Week 103 for the midgut NET cohort

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

Overall survival was defined as the time in months from the first injection of lanreotide Autogel® 120 mg every 14 days to death due to any cause. Median overall survival was estimated using the Kaplan Meier method for each cohort.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Overall Survival	NA months The median overall survival from the Kaplan Meier model was not reached for this cohort.	NA months The median overall survival from the Kaplan Meier model was not reached for this cohort.	—

SECONDARY outcome

Timeframe: Weeks 12, 24, 36, 48, 60 (for both cohorts) and Weeks 72, 84, and 96 (for midgut cohort)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

The ORR was defined as the percentage of subjects who achieve either complete response (CR) or partial response (PR) according to RECIST v1.0 criteria. ORR was evaluated every 12 weeks and results are presented for each cohort.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Objective Response Rate (ORR) Week 12	0.0 percentage of subjects Interval 0.0 to 7.4	0.0 percentage of subjects Interval 0.0 to 7.0	—
Objective Response Rate (ORR) Week 24	0.0 percentage of subjects Interval 0.0 to 7.4	0.0 percentage of subjects Interval 0.0 to 7.0	—
Objective Response Rate (ORR) Week 36	0.0 percentage of subjects Interval 0.0 to 7.4	0.0 percentage of subjects Interval 0.0 to 7.0	—
Objective Response Rate (ORR) Week 48	0.0 percentage of subjects Interval 0.0 to 7.4	0.0 percentage of subjects Interval 0.0 to 7.0	—
Objective Response Rate (ORR) Week 60	0.0 percentage of subjects Interval 0.0 to 7.4	2.0 percentage of subjects Interval 0.0 to 10.4	—
Objective Response Rate (ORR) Week 72	—	3.9 percentage of subjects Interval 0.5 to 13.5	—
Objective Response Rate (ORR) Week 84	—	2.0 percentage of subjects Interval 0.0 to 10.4	—
Objective Response Rate (ORR) Week 96	—	2.0 percentage of subjects Interval 0.0 to 10.4	—

SECONDARY outcome

Timeframe: Weeks 24 and 48

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

The DCR was defined as the percentage of subjects who achieved CR plus PR plus Stable Disease (SD), evaluated according to RECIST v1.0 criteria. The DCR at Weeks 24 and 48 is presented for each cohort.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Disease Control Rate (DCR) Week 24	43.8 percentage of subjects Interval 29.5 to 58.8	58.8 percentage of subjects Interval 44.2 to 72.4	—
Disease Control Rate (DCR) Week 48	22.9 percentage of subjects Interval 12.0 to 37.3	33.3 percentage of subjects Interval 20.8 to 47.9	—

SECONDARY outcome

Timeframe: From Day 1 up to Week 60 for the panNET cohort and Week 103 for the midgut NET cohort

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

Best overall response was defined as the best response recorded from the initiation of treatment until disease progression, according to RECIST v1.0 evaluation. The percentage of subjects in each response category and those who were non-evaluable (i.e. with no tumour assessment after the start of study treatment) throughout the study are presented for each cohort.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Best Overall Response Rate Not evaluable	0.0 percentage of subjects Interval 0.0 to 7.4	2.0 percentage of subjects Interval 0.0 to 10.4	—
Best Overall Response Rate CR	0.0 percentage of subjects Interval 0.0 to 7.4	0.0 percentage of subjects Interval 0.0 to 7.0	—
Best Overall Response Rate PR	0.0 percentage of subjects Interval 0.0 to 7.4	3.9 percentage of subjects Interval 0.5 to 13.5	—
Best Overall Response Rate SD	66.7 percentage of subjects Interval 51.6 to 79.6	68.6 percentage of subjects Interval 54.1 to 80.9	—
Best Overall Response Rate PD	31.3 percentage of subjects Interval 18.7 to 46.3	23.5 percentage of subjects Interval 12.8 to 37.5	—

SECONDARY outcome

Timeframe: From Day 1 up to Week 60 for the panNET cohort and Week 103 for the midgut NET cohort

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

Median duration of SD was the time from first injection of lanreotide Autogel® 120 mg every 14 days until the first occurrence of PD by central assessment. Disease progression was assessed by tumour response evaluation according to RECIST v1.0, every 12 weeks, measured using the same imaging technique (CT scan or MRI) for each subject throughout the study. Median duration of stable disease was estimated using the Kaplan Meier method for each cohort.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Median Duration of Stable Disease	8.3 months Interval 8.0 to 13.8	13.8 months Interval 8.6 to 95% confidence interval upper limit could not be calculated as an insufficient number of events were observed.	—

SECONDARY outcome

Timeframe: Screening/Baseline (Day 1)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

A univariate cox proportional hazards model was used to assess whether the following factors were associated with PFS:

• Hepatic tumour load: >25% versus reference ≤25%
• Tumour Grade: Grade 2 versus reference Grade 1,
• Previous surgery of the primary tumour: No versus reference Yes,
• Proliferation index Ki67: ≥10% versus reference <10%
• Duration of treatment with lanreotide Autogel® 120 mg every 28 days by category: ≥median value versus reference <median value,
• Age by category: ≥65 years versus reference <65 years,
• Time from diagnosis to study entry by category: ≥3 years versus reference <3 years,
• Time interval between the two CT scans (pre-screening/screening): ≥12 months versus reference <12 months and
• Symptoms (diarrhoea or flushing at baseline): No versus reference Yes.

Each factor was assessed for its importance in the Cox model for PFS in a univariate fashion.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Factors Associated With PFS Ki67: ≥10% Vs <10%	3.60 Hazard Ratio Interval 1.39 to 9.32	2.26 Hazard Ratio Interval 0.67 to 7.6	—
Factors Associated With PFS Tumour Grade: 2 Vs 1	0.68 Hazard Ratio Interval 0.32 to 1.45	0.90 Hazard Ratio Interval 0.46 to 1.77	—
Factors Associated With PFS Age: ≥65 years Vs <65 years	1.55 Hazard Ratio Interval 0.79 to 3.06	1.15 Hazard Ratio Interval 0.58 to 2.31	—
Factors Associated With PFS Hepatic tumour load: >25% Vs ≤25%	0.96 Hazard Ratio Interval 0.4 to 2.32	1.54 Hazard Ratio Interval 0.7 to 3.4	—
Factors Associated With PFS Previous surgery: No Vs Yes	1.04 Hazard Ratio Interval 0.53 to 2.04	2.14 Hazard Ratio Interval 0.83 to 5.52	—
Factors Associated With PFS Duration of treatment with lanreotide Autogel® 120 mg every 28 days: ≥median Vs <median	0.68 Hazard Ratio Interval 0.34 to 1.34	0.76 Hazard Ratio Interval 0.4 to 1.47	—
Factors Associated With PFS Time from diagnosis: ≥3 years Vs <3 years	0.49 Hazard Ratio Interval 0.25 to 0.96	0.94 Hazard Ratio Interval 0.49 to 1.82	—
Factors Associated With PFS Time between CT scans: ≥12 months Vs <12 months	0.47 Hazard Ratio Interval 0.24 to 0.94	0.72 Hazard Ratio Interval 0.37 to 1.39	—
Factors Associated With PFS Symptoms: No Vs Yes	2.55 Hazard Ratio Interval 0.89 to 7.28	1.32 Hazard Ratio Interval 0.68 to 2.56	—

SECONDARY outcome

Timeframe: Baseline (Day 1), Weeks 8,12, 48 and end of study (approximately 64 weeks for panNET cohort and 108 weeks for midgut NET cohort)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study. Numbers analysed at each time point correspond to the number of subjects reporting episodes in the 7 days prior to the visit.

Symptom control was measured by the total number of stools (diarrhoea) and flushing episodes during the 7 days prior to the visit, reported orally by the subject to the investigator. The mean change from baseline in number of stools and flushing episodes reported at each visit is presented for each cohort.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Mean Change From Baseline in Number of Stools and Flushing Episodes Flushing - Week 48	-1.0 episodes Standard Deviation 0.0	-1.5 episodes Standard Deviation 2.1	—
Mean Change From Baseline in Number of Stools and Flushing Episodes Stools - Week 8	1.0 episodes Standard Deviation 5.5	-1.0 episodes Standard Deviation 8.2	—
Mean Change From Baseline in Number of Stools and Flushing Episodes Stools - Week 12	-1.2 episodes Standard Deviation 7.9	0.7 episodes Standard Deviation 2.5	—
Mean Change From Baseline in Number of Stools and Flushing Episodes Stools - Week 48	-1.0 episodes Standard Deviation 0.0	3.4 episodes Standard Deviation 4.8	—
Mean Change From Baseline in Number of Stools and Flushing Episodes Stools - End of Study	0.5 episodes Standard Deviation 5.4	-1.2 episodes Standard Deviation 12.2	—
Mean Change From Baseline in Number of Stools and Flushing Episodes Flushing - Week 8	0.7 episodes Standard Deviation 2.1	-3.3 episodes Standard Deviation 8.3	—
Mean Change From Baseline in Number of Stools and Flushing Episodes Flushing - Week 12	-1.0 episodes Standard Deviation 0.0	1.5 episodes Standard Deviation 10.0	—
Mean Change From Baseline in Number of Stools and Flushing Episodes Flushing - End of Study	0.0 episodes Standard Deviation 1.4	-0.5 episodes Standard Deviation 6.2	—

SECONDARY outcome

Timeframe: Baseline (Day 1) and end of study (approximately 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study. Only subjects with data available for analysis are presented.

Subjects were instructed to complete the 30 questions in the EORTC-QLQ-C30 v3.0 questionnaire at baseline and every 12 weeks throughout the study.

The global health status sub-score was assessed using the last 2 questions which represented subject's assessment of overall health & QoL. Each question was coded on a 7-point scale (1=very poor to 7=excellent). The sub-score was transformed to range from 0-100, with a high score for global health status representing a high QoL. The mean change from baseline in the transformed global health status are presented for the end of study/early withdrawal visit, with a positive change indicating an improvement in QoL.

Outcome measures

Measure	PanNET Cohort n=22 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=25 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall n=47 Participants All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Mean Change From Baseline in QoL Measured Using EORTC, QLQ-C30 v3.0 (Global Health Status Sub-score)	-0.38 score on a scale Standard Deviation 15.32	-1.33 score on a scale Standard Deviation 17.13	-0.89 score on a scale Standard Deviation 16.14

SECONDARY outcome

Timeframe: Baseline (Day 1) and end of study (approximately 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study. Only subjects with data available for analysis are presented.

Subjects were instructed to complete the EQ-5D-5L descriptive system at baseline and every 12 weeks throughout the study.

The EQ-5D-5L descriptive system comprised the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, extreme problems. The EQ-5D-5L health states, defined by the EQ-5D-5L descriptive system, was converted into a single index value with scores ranging from 0 (no problems) to 1 (extreme problems). The mean change from baseline at the end of study/early withdrawal visit is presented with a positive change from baseline in the index values indicating a worsening of symptoms.

Outcome measures

Measure	PanNET Cohort n=22 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=21 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall n=43 Participants All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Mean Change From Baseline in EQ-5D-5L v1.0 Questionnaire (Descriptive System)	-0.04 Index value Standard Deviation 0.12	0.00 Index value Standard Deviation 0.11	-0.02 Index value Standard Deviation 0.12

SECONDARY outcome

Timeframe: Baseline (Day 1) and end of study (approximately 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study. Only subjects with data available for analysis are presented.

Subjects were instructed to complete the EQ-5D-5L VAS at baseline and every 12 weeks throughout the study. The EQ-5D-5L VAS recorded the subject's self-rated health on a vertical VAS which is numbered from 0 (worst health state) to 100 (best health state). The mean change from baseline at the end of study/early withdrawal visit is presented with a positive change in the VAS indicating an improvement in symptoms.

Outcome measures

Measure	PanNET Cohort n=21 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=21 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall n=42 Participants All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Mean Change From Baseline in EQ-5D-5L v1.0 Questionnaire (VAS)	-1.90 score on a scale Standard Deviation 14.80	-1.76 score on a scale Standard Deviation 9.34	-1.83 score on a scale Standard Deviation 12.22

SECONDARY outcome

Timeframe: Baseline (Day 1) and end of study (approximately 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study. Only subjects with data available for analysis are presented.

Subjects were asked to complete the EORTC QLQ-GI.NET21 module which comprised 21 questions that used a 4-point scale (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much) to evaluate 3 defined multi-item symptom scales (endocrine, gastrointestinal and treatment related side effects), 2 single item symptoms (bone/muscle pain and concern about weight loss), 2 psychosocial scales (social function and disease-related worries) and 2 other single items (sexuality and communication). Answers were converted into grading scale, with values between 0 and 100. Each individual sub-score was transformed to range from 0 to 100. The mean change from baseline at the end of study/early withdrawal visit is presented with a higher score representing more or worse problems.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall n=99 Participants All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Mean Change From Baseline in QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21; 2006) Endocrine Symptoms	-0.53 score on a scale Standard Deviation 11.37	-5.09 score on a scale Standard Deviation 17.33	-2.96 score on a scale Standard Deviation 14.87
Mean Change From Baseline in QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21; 2006) Gastrointestinal Symptoms	-3.49 score on a scale Standard Deviation 14.24	-2.78 score on a scale Standard Deviation 15.96	-3.11 score on a scale Standard Deviation 15.02
Mean Change From Baseline in QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21; 2006) Treatment Related Symptoms	5.93 score on a scale Standard Deviation 15.64	-3.47 score on a scale Standard Deviation 14.47	1.08 score on a scale Standard Deviation 15.54
Mean Change From Baseline in QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21; 2006) Social Function	-0.79 score on a scale Standard Deviation 13.41	-9.49 score on a scale Standard Deviation 18.20	-5.43 score on a scale Standard Deviation 16.56
Mean Change From Baseline in QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21; 2006) Disease Related Worries	3.17 score on a scale Standard Deviation 15.47	-0.93 score on a scale Standard Deviation 27.40	0.99 score on a scale Standard Deviation 22.48
Mean Change From Baseline in QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21; 2006) Muscle/Bone Pain	-1.67 score on a scale Standard Deviation 33.29	0.00 score on a scale Standard Deviation 36.78	-0.76 score on a scale Standard Deviation 34.84
Mean Change From Baseline in QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21; 2006) Sexual Function	2.38 score on a scale Standard Deviation 15.82	-2.78 score on a scale Standard Deviation 26.43	0.00 score on a scale Standard Deviation 21.08
Mean Change From Baseline in QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21; 2006) Information/Communication Function	7.94 score on a scale Standard Deviation 29.64	-2.90 score on a scale Standard Deviation 9.60	2.27 score on a scale Standard Deviation 22.04
Mean Change From Baseline in QoL Questionnaire Gastrointestinal Neuroendocrine Tumour 21 (QLQ-GI.NET21; 2006) Body Image	0.00 score on a scale Standard Deviation 15.29	-7.58 score on a scale Standard Deviation 28.97	-3.97 score on a scale Standard Deviation 23.52

SECONDARY outcome

Timeframe: Baseline (Day 1) and end of study (approximately 64 weeks for panNET cohort and 108 weeks for midgut NET cohort)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study. Only subjects with data available for analysis are presented.

Nonspecific tumour peptide biomarkers (chromogranin A [CgA], neuron specific enolase [NSE] and plasma/urinary 5-hydroxyindoleacetic acid [5-HIAA]) were evaluated in both pancreas and midgut subjects at baseline and Week 12 and every 12 weeks thereafter. At all scheduled visits, except baseline, plasma/urinary 5-HIAA was only performed in subjects with symptoms of carcinoid syndrome (diarrhoea and/or flushing) or if urinary 5-HIAA was elevated (above upper limit of normal [ULN]) at baseline. Mean change from baseline values were normalised by the ULN (xULN) and are presented for each cohort.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Mean Change From Baseline in Nonspecific Tumour Biomarkers CgA	0.205 xULN Standard Deviation 1.258	0.370 xULN Standard Deviation 1.843	—
Mean Change From Baseline in Nonspecific Tumour Biomarkers NSE	0.03 xULN Standard Deviation 1.00	-0.49 xULN Standard Deviation 1.86	—
Mean Change From Baseline in Nonspecific Tumour Biomarkers Plasma 5-HIAA	-0.42 xULN Standard Deviation 1.44	3.90 xULN Standard Deviation 7.39	—

SECONDARY outcome

Timeframe: Baseline (Day 1) and end of study (approximately 64 weeks)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study. Only subjects in the panNET cohort with data available for analysis are presented.

PanNET specific tumour peptide biomarkers were evaluated in pancreas subjects at baseline. Only the tumour biomarkers that were above normal range at baseline were evaluated every 12 weeks thereafter and at the end of study visit. The mean change from baseline values in picomole/liter (pmol/L) are presented for the end of study visit.

Outcome measures

Measure	PanNET Cohort n=48 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Mean Change From Baseline in PanNet Specific Tumour Biomarkers: Pancreatic Polypeptide, Gastrin Pancreatic Polypeptide	82.7 pmol/L Standard Deviation 146.7	—	—
Mean Change From Baseline in PanNet Specific Tumour Biomarkers: Pancreatic Polypeptide, Gastrin Gastrin	-9.8 pmol/L Standard Deviation 70.7	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1) and end of study (approximately 64 weeks)

Population: The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study. Only subjects in panNET cohort with data available for analysis are presented.

PanNET specific tumour peptide biomarkers were evaluated in pancreas subjects at baseline. Only the tumour biomarkers that were above normal range at baseline were evaluated every 12 weeks thereafter and at the end of study visit. The mean change from baseline values in nanograms (ng)/L are presented for the end of study visit.

Outcome measures

Measure	PanNET Cohort n=4 Participants Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Mean Change From Baseline in PanNet Specific Tumour Biomarkers: Glucagon	5.5 ng/L Standard Deviation 36.4	—	—

Adverse Events

PanNET Cohort

Serious events: 5 serious events

Other events: 41 other events

Deaths: 1 deaths

Midgut NET Cohort

Serious events: 13 serious events

Other events: 47 other events

Deaths: 3 deaths

Overall Subjects

Serious events: 18 serious events

Other events: 88 other events

Deaths: 4 deaths

Serious adverse events

Measure	PanNET Cohort n=48 participants at risk Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 participants at risk Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall Subjects n=99 participants at risk All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Cardiac disorders Cardiac failure	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Cardiac disorders Pulseless electrical activity	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Abdominal pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Diarrhoea	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Asthenia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Chest pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders General physical health deterioration	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Immune system disorders Anaphylactic reaction	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Peritonitis	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Viral infection	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Craniocerebral injury	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Fall	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Spinal fracture	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bone neoplasm	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Spinal cord compression	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Syncope	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 4 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Vascular disorders Hypotension	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

Other adverse events

Measure	PanNET Cohort n=48 participants at risk Subjects were treated with lanreotide Autogel® 120 mg, administered as SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 48 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 48 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the panNET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Midgut NET Cohort n=51 participants at risk Subjects were treated with lanreotide Autogel® 120 mg, administered as deep SC injections, every 14 days starting from Day 1 (at a reduced dosing interval) for up to 96 weeks or until disease progression, death or unacceptable toxicity or tolerability. Subjects who had not progressed at Week 96 could continue study treatment with lanreotide Autogel® 120 mg every 14 days until 25 events (PD or death) in the midgut NET cohort had been observed. Additional visits were performed every 12 weeks until disease progression or death, or unacceptable toxicity or tolerability.	Overall Subjects n=99 participants at risk All subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Blood and lymphatic system disorders Lymphopenia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Blood and lymphatic system disorders Monocytopenia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Cardiac disorders Arrhythmia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Cardiac disorders Cardiac failure	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Cardiac disorders Heart valve incompetence	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Cardiac disorders Palpitations	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Cardiac disorders Right ventricular failure	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Cardiac disorders Tachycardia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Cardiac disorders Tricuspid valve disease	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Ear and labyrinth disorders Deafness	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Ear and labyrinth disorders Deafness unilateral	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Ear and labyrinth disorders Ear pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Ear and labyrinth disorders Hypoacusis	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Ear and labyrinth disorders Vertigo	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Ear and labyrinth disorders Vertigo positional	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Eye disorders Diplopia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Eye disorders Dry eye	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Eye disorders Eye pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Eye disorders Eye pruritus	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Eye disorders Glaucoma	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Eye disorders Ocular hyperaemia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Abdominal distension	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	11.8% 6/51 • Number of events 7 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	6.1% 6/99 • Number of events 7 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Abdominal pain	14.6% 7/48 • Number of events 13 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	23.5% 12/51 • Number of events 16 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	19.2% 19/99 • Number of events 29 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Abdominal pain lower	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Abdominal pain upper	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	11.8% 6/51 • Number of events 7 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	8.1% 8/99 • Number of events 9 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Anal incontinence	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Anorectal discomfort	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Ascites	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Constipation	4.2% 2/48 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	4.0% 4/99 • Number of events 6 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Diarrhoea	29.2% 14/48 • Number of events 20 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	52.9% 27/51 • Number of events 35 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	41.4% 41/99 • Number of events 55 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Dry mouth	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Dyspepsia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Faeces discoloured	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Flatulence	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	11.8% 6/51 • Number of events 8 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	7.1% 7/99 • Number of events 9 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Gastrooesophageal reflux disease	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Gingival bleeding	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Gingival pain	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Glossodynia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Haematochezia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Hernial eventration	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Inguinal hernia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Nausea	10.4% 5/48 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	11.8% 6/51 • Number of events 9 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	11.1% 11/99 • Number of events 14 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Oral pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Pancreatic failure	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Proctalgia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Steatorrhoea	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.9% 3/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.1% 5/99 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Stomatitis	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Toothache	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Vomiting	12.5% 6/48 • Number of events 9 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	7.8% 4/51 • Number of events 4 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	10.1% 10/99 • Number of events 13 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Asthenia	8.3% 4/48 • Number of events 24 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	7.8% 4/51 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	8.1% 8/99 • Number of events 29 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Chest pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.9% 3/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Fatigue	14.6% 7/48 • Number of events 8 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	15.7% 8/51 • Number of events 11 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	15.2% 15/99 • Number of events 19 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Gait disturbance	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Hunger	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Influenza like illness	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.9% 3/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	4.0% 4/99 • Number of events 4 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Injection site bruising	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Injection site pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Malaise	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Medical device site pain	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Oedema peripheral	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	4.0% 4/99 • Number of events 4 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Peripheral swelling	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.9% 3/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Polyp	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
General disorders Pyrexia	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	4.0% 4/99 • Number of events 7 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Hepatobiliary disorders Bile duct stone	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Hepatobiliary disorders Cholelithiasis	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.9% 3/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Hepatobiliary disorders Hepatic failure	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Hepatobiliary disorders Liver injury	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Immune system disorders Drug hypersensitivity	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Bronchitis	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Carbuncle	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Cystitis	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Cystitis bacterial	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Diverticulitis	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Folliculitis	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Herpes zoster	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Influenza	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.9% 3/51 • Number of events 6 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.1% 5/99 • Number of events 8 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Lower respiratory tract infection	2.1% 1/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.9% 3/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	4.0% 4/99 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Nasopharyngitis	14.6% 7/48 • Number of events 7 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	9.8% 5/51 • Number of events 6 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	12.1% 12/99 • Number of events 13 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Respiratory tract infection	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Tonsillitis	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Upper respiratory tract infection	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Infections and infestations Urinary tract infection	8.3% 4/48 • Number of events 6 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.1% 5/99 • Number of events 7 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Fall	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Incision site pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Incisional hernia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Muscle strain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Post procedural complication	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Radiation skin injury	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Injury, poisoning and procedural complications Skin abrasion	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Alanine aminotransferase increased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Aspartate aminotransferase abnormal	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Aspartate aminotransferase increased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Bacterial test positive	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Blood alkaline phosphatase increased	6.2% 3/48 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	4.0% 4/99 • Number of events 4 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Blood bilirubin increased	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Blood chromogranin A increased	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Blood creatinine increased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Blood glucose decreased	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Blood glucose increased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Blood potassium increased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Blood triglycerides increased	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Blood urea increased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Blood urine present	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations C-reactive protein increased	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Gamma-glutamyltransferase abnormal	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Gamma-glutamyltransferase decreased	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Gamma-glutamyltransferase increased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Glycosylated haemoglobin increased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Lymphocyte count decreased	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Neutrophil count decreased	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Platelet count decreased	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Specific gravity urine increased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Urine ketone body present	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Investigations Weight decreased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Carbohydrate intolerance	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Decreased appetite	10.4% 5/48 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	7.1% 7/99 • Number of events 7 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hyperglycaemia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hypernatraemia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hyperuricaemia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hypoalbuminaemia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hypocalcaemia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hypoglycaemia	2.1% 1/48 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 4 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Hyponatraemia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Malnutrition	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Metabolism and nutrition disorders Vitamin D deficiency	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	9.8% 5/51 • Number of events 7 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.1% 5/99 • Number of events 7 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Back pain	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	4.0% 4/99 • Number of events 4 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Exostosis	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Intervertebral disc degeneration	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Joint swelling	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.9% 3/51 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Mobility decreased	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Muscle spasms	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 4 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Osteoarthritis	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Osteoporosis	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Pain in extremity	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 4 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Periarthritis	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Rheumatoid arthritis	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Musculoskeletal and connective tissue disorders Spinal pain	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to liver	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Ageusia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Aphasia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Balance disorder	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Dizziness	6.2% 3/48 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	9.8% 5/51 • Number of events 7 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	8.1% 8/99 • Number of events 10 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Dizziness postural	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Head discomfort	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Headache	6.2% 3/48 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	7.8% 4/51 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	7.1% 7/99 • Number of events 8 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Lethargy	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Poor quality sleep	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Presyncope	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Sciatica	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Syncope	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Taste disorder	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Nervous system disorders Tremor	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Psychiatric disorders Acrophobia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Psychiatric disorders Confusional state	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Psychiatric disorders Insomnia	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Psychiatric disorders Mood altered	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Psychiatric disorders Panic attack	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Psychiatric disorders Sleep disorder	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Renal and urinary disorders Chronic kidney disease	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Renal and urinary disorders Dysuria	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Renal and urinary disorders Haematuria	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Renal and urinary disorders Urethral stenosis	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Reproductive system and breast disorders Gynaecomastia	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Asthma	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Cough	6.2% 3/48 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.9% 3/51 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	6.1% 6/99 • Number of events 6 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Dysphonia	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	7.8% 4/51 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	4.0% 4/99 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.0% 3/99 • Number of events 3 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Increased upper airway secretion	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Orthopnoea	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Respiratory, thoracic and mediastinal disorders Sputum discoloured	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Skin and subcutaneous tissue disorders Hyperhidrosis	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Skin and subcutaneous tissue disorders Photosensitivity reaction	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Skin and subcutaneous tissue disorders Pruritus	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	5.9% 3/51 • Number of events 4 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	4.0% 4/99 • Number of events 5 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Skin and subcutaneous tissue disorders Pruritus generalised	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Skin and subcutaneous tissue disorders Rash	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Skin and subcutaneous tissue disorders Skin fissures	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Skin and subcutaneous tissue disorders Skin irritation	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Surgical and medical procedures Injection	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Vascular disorders Deep vein thrombosis	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Vascular disorders Flushing	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	17.6% 9/51 • Number of events 14 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	11.1% 11/99 • Number of events 16 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Vascular disorders Haematoma	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Vascular disorders Hot flush	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	3.9% 2/51 • Number of events 14 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 14 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Vascular disorders Hypertension	4.2% 2/48 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	17.6% 9/51 • Number of events 9 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	11.1% 11/99 • Number of events 11 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Vascular disorders Peripheral venous disease	0.00% 0/48 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Vascular disorders Venous thrombosis limb	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	0.00% 0/51 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	1.0% 1/99 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.
Gastrointestinal disorders Haemorrhoids	2.1% 1/48 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 1/51 • Number of events 1 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.	2.0% 2/99 • Number of events 2 • Treatment emergent adverse events were recorded from the first dose of lanreotide Autogel® 120 mg on Day 1 until 28 days after the last treatment. Overall time frame of up to a maximum of 64 weeks for panNET cohort and 108 weeks for midgut NET (and overall) cohort. The FAS included all subjects who received at least one dose of lanreotide Autogel® 120 mg every 14 days during the study.

Additional Information

Ipsen Medical Director

Ipsen

Phone: see email

Email: clinical.trials@ipsen.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place